Chapter 26: GERD & Peptic Ulcer Disease Treatment

Chapter 26 offers an essential guide to the diagnosis and management of two widespread gastrointestinal disorders, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), both of which can significantly diminish a patient’s health-related quality of life. GERD is typically classified by whether symptoms occur without esophageal tissue injury or with actual erosions, resulting from the failure of defense mechanisms like the lower esophageal sphincter (LES) and esophageal clearance. Key risk factors contributing to GERD include obesity, delayed gastric emptying, and intake of specific foods or medications that decrease LES tone. PUD is most commonly attributed to infection by Helicobacter pylori or chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs), both of which disrupt the delicate homeostasis between acid production (HCl and pepsin) and mucosal protective layers. The therapeutic strategy for both conditions begins with critical lifestyle changes, such as weight reduction and avoiding offending substances. Pharmacological treatment aims to reduce acid secretion, heal the mucosa, and prevent complications. Drug classes used range from over-the-counter antacids for mild, intermittent heartburn, to Histamine-2 Receptor Antagonists (H2RAs), and, most potently, Proton Pump Inhibitors (PPIs), which provide superior symptom relief and tissue healing for moderate-to-severe disease. Eradicating H. pylori requires complex multi-drug regimens, typically combining a PPI with two or more antibiotics (e.g., amoxicillin, clarithromycin, metronidazole), chosen based on known resistance and allergy profiles. For NSAID-induced ulcers, management includes discontinuing the NSAID or co-prescribing a protective agent like a PPI or misoprostol. The chapter emphasizes that treatment choice, whether initiating a step-up or step-down approach, must be individualized, considering potential long-term PPI side effects (like bone fractures and infections), drug interactions (such as the clopidogrel-omeprazole interaction), and the unique needs of special populations, like geriatric patients or pregnant women.